User profiles for T. B. Fessenden
 | Tim B FessendenScientific Editor, Rockefeller University Press Verified email at rockefeller.edu Cited by 532 |
[PDF][PDF] Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor
immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, …
immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, …
Tissue site and the cancer immunity cycle
Checkpoint blockade immunotherapy (CBT) has revolutionized cancer treatment; however,
the cellular and molecular factors that govern responsiveness to immunotherapy remain …
the cellular and molecular factors that govern responsiveness to immunotherapy remain …
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Imidazoquinolines (IMDs), such as resiquimod (R848), are of great interest as potential
cancer immunotherapies because of their ability to activate Toll-like receptor 7 (TLR7) and/or …
cancer immunotherapies because of their ability to activate Toll-like receptor 7 (TLR7) and/or …
[HTML][HTML] Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
…, V Krishnan, J Kach, H Brechka, TB Fessenden… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with
proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority …
proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority …
[HTML][HTML] Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes
CA Fordyce, KT Patten, TB Fessenden… - Breast Cancer …, 2012 - Springer
Introduction Tumors are characterized by alterations in the epithelial and stromal compartments,
which both contribute to tumor promotion. However, where, when, and how the tumor …
which both contribute to tumor promotion. However, where, when, and how the tumor …
Dia1-dependent adhesions are required by epithelial tissues to initiate invasion
TB Fessenden, Y Beckham, M Perez-Neut… - Journal of Cell …, 2018 - rupress.org
… Fessenden’s present address is David H. Koch Institute for Integrative Cancer Research, …
Author contributions: TB Fessenden conceived the study, performed experiments and …
Author contributions: TB Fessenden conceived the study, performed experiments and …
[HTML][HTML] Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
TB Fessenden, LE Stopfer, F Chatterjee… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background For effective tumor elimination, cytotoxic CD8+ T cells must recognize tumor-derived
antigens presented on class I major histocompatibility complex (MHC-I). Despite a …
antigens presented on class I major histocompatibility complex (MHC-I). Despite a …
[HTML][HTML] A team effort: natural killer cells on the first leg of the tumor immunity relay race
TB Fessenden, E Duong, S Spranger - Journal for immunotherapy of …, 2018 - Springer
Recent work by Böttcher and colleagues defines a new role for Natural Killer cells in the anti-tumor
immune response, arriving early into the tumor microenvironment before passing the …
immune response, arriving early into the tumor microenvironment before passing the …
[BOOK][B] Cytoskeletal Control of Tissue Shape Changes
TB Fessenden - 2017 - search.proquest.com
The collective actions of epithelial cells drive tissue shape changes, whether these are tightly
organized during development or disorganized as during cancer invasion. In both cases, …
organized during development or disorganized as during cancer invasion. In both cases, …
[PDF][PDF] Chatter ee
TB Fessenden, LE Stopfer - F., Zulueta …, 2022 - scholarlypublications …
Background For effective tumor elimination, cytotoxic CD8+ T cells must recognize tumor-derived
antigens presented on class I major histocompatibility complex (MHC-I). Despite a …
antigens presented on class I major histocompatibility complex (MHC-I). Despite a …